WallStreetZenWallStreetZen

NASDAQ: XGN
Exagen Inc Stock

Open Broker Account
$2.43-0.06 (-2.41%)
Updated Dec 5, 2022
XGN Price
$2.43
Fair Value Price
$6.91
Market Cap
$39.66M
52 Week Low
$2.10
52 Week High
$11.69
P/E
-1.04x
P/B
0.71x
P/S
1.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$45.42M
Earnings
-$40.09M
Gross Margin
49.7%
Operating Margin
-82.46%
Profit Margin
-88.3%
Debt to Equity
0.81
Operating Cash Flow
-$32M
Beta
1.42
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

XGN Overview

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Zen Score

Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XGN ($2.43) is undervalued by 64.82% relative to our estimate of its Fair Value price of $6.91 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XGN ($2.43) is significantly undervalued by 64.82% relative to our estimate of its Fair Value price of $6.91 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
XGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XGN due diligence checks available for Premium users.

Be the first to know about important XGN news, forecast changes, insider trades & much more!

XGN News

Valuation

XGN fair value

Fair Value of XGN stock based on Discounted Cash Flow (DCF)
Price
$2.43
Fair Value
$6.91
Undervalued by
64.82%
XGN ($2.43) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XGN ($2.43) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.04x
Industry
35.84x
Market
21.63x

XGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.71x
Industry
4.38x
XGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XGN's financial health

Profit margin

Revenue
$14.7M
Net Income
-$8.1M
Profit Margin
-55%
XGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XGN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$101.6M
Liabilities
$45.4M
Debt to equity
0.81
XGN's short-term assets ($82.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XGN's short-term assets ($82.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.7M
Investing
-$879.0k
Financing
-$22.0k
XGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XGN vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
XGN$39.66M-2.41%-1.04x0.71x
SERA$38.77M-5.30%-1.11x0.36x
AWH$45.05M-2.69%-1.34x4.03x
PMD$32.06M-0.96%-15.78x2.74x
BWAY$31.24M+2.20%-2.91x0.64x

Exagen Stock FAQ

What is Exagen's quote symbol?

NASDAQ: XGN) Exagen trades on the NASDAQ under the ticker symbol XGN. Exagen stock quotes can also be displayed as NASDAQ: XGN.

If you're new to stock investing, here's how to buy Exagen stock.

What is the 52 week high and low for Exagen (NASDAQ: XGN)?

(NASDAQ: XGN) Exagen's 52-week high was $11.69, and its 52-week low was $2.10. It is currently -79.21% from its 52-week high and 15.71% from its 52-week low.

How much is Exagen stock worth today?

(NASDAQ: XGN) Exagen currently has 16,319,488 outstanding shares. With Exagen stock trading at $2.43 per share, the total value of Exagen stock (market capitalization) is $39.66M.

Exagen stock was originally listed at a price of $18.58 in Sep 19, 2019. If you had invested in Exagen stock at $18.58, your return over the last 3 years would have been -86.92%, for an annualized return of -49.24% (not including any dividends or dividend reinvestments).

How much is Exagen's stock price per share?

(NASDAQ: XGN) Exagen stock price per share is $2.43 today (as of Dec 5, 2022).

What is Exagen's Market Cap?

(NASDAQ: XGN) Exagen's market cap is $39.66M, as of Dec 6, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Exagen's market cap is calculated by multiplying XGN's current stock price of $2.43 by XGN's total outstanding shares of 16,319,488.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.